Suchitra Sundaram, MD, discusses several exciting studies to be presented in diffuse large B-cell lymphoma (DLBCL) at this year's ASH conference, including the Smart Stop trial assessing lenalidomide, rituximab, tafasitamab, and acalabrutinib as initial therapy to potentially reduce chemoimmunotherapy cycles.
Additionally, Dr Sundaram previews a study that explores mosunetuzumab and polatuzumab in older patients with DLBCL and another trial that investigates glofitamab with R-CHOP, using ctDNA as a biomarker. Notably, trials like ELM-2, with odronextamab in relapsed DLBCL, and one on a five-drug combination in refractory DLBCL, bring promise to the field.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASH 2023: Anticipating Impactful Data in DLBCL - Medscape - Dec 01, 2023.
Comments